| Dr Pacifico M Tuason, MD | |
|
55 Fruit St, Grj 405, Boston, MA 02114-2621 | |
| (617) 643-4256 | |
| Not Available |
| Full Name | Dr Pacifico M Tuason |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 32 Years |
| Location | 55 Fruit St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184713315 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 209340 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
News Archive
Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of obesity to promote cancer progression. In their report published online in the journal Clinical Cancer Research, the research team describes finding an association between obesity and an overabundance of a factor called PlGF (placental growth factor) and that PlGF's binding to its receptor VEGFR-1, which is expressed on immune cells within tumors, promotes tumor progression.
Yesterday (8th May 2018), the Government of the Democratic Republic of the Congo declared a new outbreak of Ebola in the rural northwest of the country. This came after two cases of Ebola were confirmed in regions of Bikoro.
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.
› Verified 2 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of obesity to promote cancer progression. In their report published online in the journal Clinical Cancer Research, the research team describes finding an association between obesity and an overabundance of a factor called PlGF (placental growth factor) and that PlGF's binding to its receptor VEGFR-1, which is expressed on immune cells within tumors, promotes tumor progression.
Yesterday (8th May 2018), the Government of the Democratic Republic of the Congo declared a new outbreak of Ebola in the rural northwest of the country. This came after two cases of Ebola were confirmed in regions of Bikoro.
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.
› Verified 2 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of obesity to promote cancer progression. In their report published online in the journal Clinical Cancer Research, the research team describes finding an association between obesity and an overabundance of a factor called PlGF (placental growth factor) and that PlGF's binding to its receptor VEGFR-1, which is expressed on immune cells within tumors, promotes tumor progression.
Yesterday (8th May 2018), the Government of the Democratic Republic of the Congo declared a new outbreak of Ebola in the rural northwest of the country. This came after two cases of Ebola were confirmed in regions of Bikoro.
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.
› Verified 2 days ago
| Entity Name | The Shriners Hospital For Children |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285078444 PECOS PAC ID: 5496947301 Enrollment ID: O20131219000781 |
News Archive
Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of obesity to promote cancer progression. In their report published online in the journal Clinical Cancer Research, the research team describes finding an association between obesity and an overabundance of a factor called PlGF (placental growth factor) and that PlGF's binding to its receptor VEGFR-1, which is expressed on immune cells within tumors, promotes tumor progression.
Yesterday (8th May 2018), the Government of the Democratic Republic of the Congo declared a new outbreak of Ebola in the rural northwest of the country. This came after two cases of Ebola were confirmed in regions of Bikoro.
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Pacifico M Tuason, MD 55 Fruit St, Grj 405, Boston, MA 02114-2621 Ph: (617) 643-4256 | Dr Pacifico M Tuason, MD 55 Fruit St, Grj 405, Boston, MA 02114-2621 Ph: (617) 643-4256 |
News Archive
Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of obesity to promote cancer progression. In their report published online in the journal Clinical Cancer Research, the research team describes finding an association between obesity and an overabundance of a factor called PlGF (placental growth factor) and that PlGF's binding to its receptor VEGFR-1, which is expressed on immune cells within tumors, promotes tumor progression.
Yesterday (8th May 2018), the Government of the Democratic Republic of the Congo declared a new outbreak of Ebola in the rural northwest of the country. This came after two cases of Ebola were confirmed in regions of Bikoro.
Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of $6.0 million. Excluding acquisition and integration related charges, the transaction is expected to be accretive to Solta Medical's earnings within twelve months.
Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.
› Verified 2 days ago
Stephen G. Flynn, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6000 | |
Dr. Dusan Hanidziar, M.D., PH.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 55 Fruit St, Gray-bigelow 444, Boston, MA 02114 Phone: 617-726-3030 | |
Dr. Michael Christopher Lubrano, M.D., M.P.H. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-732-8210 | |
Vahid Kiarad, M.D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 617-667-7000 | |
Kendrick M Shaw, MD, PHD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 Phone: 617-726-3030 | |
John William Carl Carter Mallett, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-732-5500 | |
Dr. David Joswick, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 800 Washington St, Boston, MA 02111 Phone: 617-636-5000 |